Familial dysbetalipoproteinemia: highly atherogenic and underdiagnosed disorder
https://doi.org/10.15829/1728-8800-2021-2893
Abstract
Familial dysbetalipoproteinemia (FD) is a genetic, highly atherogenic disorder. The penetrance of FD depends on the patient’s lifestyle and concomitant diseases. Despite the fact that FD was described almost half a century ago, it is still insufficiently studied and is extremely rarely diagnosed. In actual clinical practice, physicians do not have clear understanding of clinical course and genetic basis of FD. The aim was to present the most complete, but at the same time a critical review with a modern view on FD. We analyzed Russian and foreign publications from following electronic databases: PubMed, eLIBRARY, Google Scholar. As a result, the phenotypic features and genetic variability of the disease were considered and the main issues of diagnosis and treatment of patients with FD were discussed. The data presented will help the clinician to timely suspect the FD, conduct a full range of investigations and prescribe evidence-based lipid-lowering therapy.
About the Authors
A. V. Blokhina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Clinical resident, laboratory researcher, laboratory of Clinomics. SPIN:1103-6168.
Moscow, +7 (916) 170-87-25
A. I. Ershova
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
MD, PhD, Head of the Laboratory of Clinomics. SPIN: 5292-5612.
Moscow
A. N. Meshkov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
MD, PhD, Head of the Laboratory of Molecular genetics. SPIN: 6340-5187.
Moscow
O. M. Drapkina
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
MD, Professor, Director of the National Medical Research Center for Therapy and Preventive Medicine. SPIN: 4456-1297.
Moscow
References
1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.
2. Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat of atherosclerosis Russian recommendations VII revision. Journal of atherosclerosis and dyslipisemias. 2020;11(1):38. (In Russ.) doi:10.34687/2219-8202.JAD.2020.01.0002.
3. Blum CB. Type III Hyperlipoproteinemia: still worth considering? Prog Cardiovasc Dis. 2016;59(2):119-24. doi:10.1016/j.pcad.2016.07.007.
4. Chepetova TV, Meshkov AN. Hypertriglyceridemia: etiology, pathogenesis, diagnostics. Cardiovascular Therapy and Prevention. 2006;5(5):94-100. (In Russ.)
5. Koopal C, Marais AD, Westerink J, et al. Autosomal dominant familial dysbetalipoproteinemia: a pathophysiological framework and practical approach to diagnosis and therapy. J Clin Lipidol. 2017;11(1):12-23. doi:10.1016/j.jacl.2016.10.001.
6. Koopal C, Marais AD, Visseren FL. Familial dysbetalipop roteinemia: an underdiagnosed lipid disorder. Curr Opin Endocrinol Diabetes Obes. 2017;24(2):133-9. doi:10.1097/MED.0000000000000316.
7. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. J Lipid Res. 2009;50:S183-8. doi:10.1194/jlr.R800069-JLR200.
8. Marais AD, Solomon GAE, Blom DJ. Dysbetalipoproteinaemia: a mixed hyperlipidaemia of remnant lipoproteins due to mutations in apolipoprotein E. Crit Rev Clin Lab Sci. 2014;51(1):46-62. doi:10.3109/10408363.2013.870526.
9. Rall SC, Newhouse YM, Clarke HR, et al. Type III hyperlipo-proteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant. J Clin Invest. 1989;83(4):1095-101. doi:10.1172/JCI113988.
10. Vezeridis AM, Drosatos K, Zannis VI. Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4. J Lipid Res. 2011;52(1):45-56. doi:10.1194/jlr.M008409.
11. Limonova AS, Ershova AI, Meshkov AN, et al. Case Report: Hypertriglyceridemia and Premature Atherosclerosis in a Patient With Apolipoprotein E Gene ε2ε1 Genotype. Front Cardiovasc Med. 2020;7:1-6. doi:10.3389/fcvm.2020.585779.
12. De Beer F, Stalenhoef AF, Hoogerbrugge N, et al. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158’ Cys) homozygotes is associated with hyperinsulinemia. Arterioscler Thromb Vasc Biol. 2002;22(2):294-9. doi:10.1161/hq0202.102919.
13. Henneman P, Van Der Sman-de Beer F, Moghaddam PH, et al. The expression of type III hyperlipoproteinemia: involvement of lipolysis genes. Eur J Hum Genet. 2009;17(5):620-8. doi:10.1038/ejhg.2008.202.
14. Evans D, Beil FU. The D9N, N291S and S447X variants in the lipoprotein lipase (LPL) gene are not associated with Type III Hyperlipidemia. BMC Med Genet. 2007;8(1):1-6. doi:10.1186/1471-2350-8-56.
15. Hopkins PN, Brinton EA, Nanjee MN. Hyperlipoproteinemia type 3: the forgotten phenotype. CurrAtheroscler Rep. 2014;16(9):440. doi:10.1007/s11883-014-0440-2.
16. Boot CS, Luvai A, Neely RD. The clinical and laboratory investigation of dysbetalipoproteinemia. Crit Rev Clin Lab Sci. 2020;57(7):458-69. doi:10.1080/10408363.2020.1745142.
17. Pallazola VA, Sathiyakumar V, Park J, et al. Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyper-lipoproteinemia). Arch Med Sci. 2020;16(5):993. doi:10.5114/aoms.2019.86972.
18. Malyshev PP, Tyurina AV, Rozhkova TA, et al. Familial dysbetalipoproteinemia (type III hyperlipoproteinemia). Eurasian Heart J. 2019;(1):42-6. (In Russ.)
19. Sniderman AD, de Graaf J, Thanassoulis G, et al. The spectrum of type III hyperlipoproteinemia. J Clin Lipidol. 2018;12(6): 1383-9. doi:10.1016/j.jacl.2018.09.006.
20. Boot CS, Middling E, Allen J, et al. Evaluation of the non-HDL cholesterol to apolipoprotein B ratio as a screening test for dysbetalipoproteinemia. Clin Сhem. 2019;65(2):313-20. doi:10.1373/clinchem.2018.292425.
21. Rothschild M, Duhon G, Riaz R, et al. Pathognomonic palmar crease xanthomas of apolipoprotein E2 homozygosity-familial dysbetalipoproteinemia. JAMA dermatology. 2016;152(11):1275-6. doi:10.1001/jamadermatol.2016.2223.
22. Blom DJ, Byrnes P, Jones S, et al. Dysbetalipoproteinaemia — clinical and pathophysiological features. S Afr Med J. 2002; 92(11):892-7.
23. Morganroth J, Levy RI, Fredrickson DS. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Int Med.1975;82(2):158-74. doi:10.7326/0003-4819-82-2-158.
24. Heidemann BE, Wolters FJ, Kavousi M, et al. Risk factors for the presence and development of Familial Dysbetalipoproteinemia in subjects from the general population with an APOE2E2 genotype. Eur Heart J. 2020;41(Suppl 2):2982. doi:10.1093/ehjci/ehaa946.2982.
25. Koopal C, Retterstøl K, Sjouke B, et al. Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study. Atherosclerosis. 2015;240(1):90-7. doi:10.1016/j.atherosclerosis.2015.02.046.
26. Smelt AHM, De Beer F. Apolipoprotein E and familial dysbetalip oproteinemia: clinical, biochemical, and genetic aspects. Seminars in vascular medicine. 2004;4(3):249-57. doi:10.1055/s-2004-861492.
27. Basaran A. Pregnancy-induced hyperlipoproteinemia: review of the literature. Reprod Sci. 2009;16(5):431-7. doi:10.1177/1933719108330569.
28. Chuang TY, Chao CL, Lin BJ, et al. Gestational hyperlipidemic pancreatitis caused by type III hyperlipoproteinemia with apolipoprotein E2/E2 homozygote. Pancreas. 2009;38(6):716-7. doi:10.1097/MPA.0b013e3181ac6dc1.
29. Castro Cabezas M, Botham KM, Mamo JC, et al. Novel aspects of nonfasting lipemia in relation to vascular biology. Int J Vasc Med. 2012;2012:419015. doi:10.1155/2012/419015.
30. Ershova AI, Al Rashi DO, Ivanova AA, et al. Secondary hyper-lipidemias: etiology and pathogenesis. Russian Journal of Car-diology. 2019;(5):74-81. (In Russ.) doi:10.15829/1560-4071-2019-5-74-81.
31. Saito T, Matsunaga A, Fukunaga M, et al. Apolipoprotein E– related glomerular disorders. Kidney Int. 2020;97(2):279-88. doi:10.1016/j.kint.2019.10.031.
32. Kawanishi K, Sawada A, Ochi A, et al. Glomerulopathy with homozygous apolipoprotein e2: a report of three cases and review of the literature. Case Rep Nephrol Dial. 2013;3(2):128-35. doi:10.1159/000356849.
33. Varbo A, Benn M, Tybjærg-Hansen A, et al. Remnant chole-sterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427-36. doi:10.1016/j.jacc.2012.08.1026.
34. Hopkins PN, Wu LL, Hunt SC, et al. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol. 2005;45(7):1003-12. doi:10.1016/j.jacc.2004.11.062.
35. Koopal C, Geerlings MI, Muller M, et al. The relation between apolipoprotein E (APOE) genotype and peripheral artery disease in patients at high risk for cardiovascular disease. Atherosclerosis. 2016;246:187-92. doi:10.1016/j.atherosclerosis.2016.01.009.
36. Lumsden AL, Mulugeta A, Zhou A, et al. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. EBioMedicine. 2020;59:102954. doi:10.1016/j.ebiom.2020.102954.
37. Kukava NG, Titov BV, Osmak GJ, et al. Multilocus analysis of genetic susceptibility to myocardial infarction in Russians: replication study. Acta Naturae. 2017;9(4):74-83.
38. Khan TA, Shah T, Prieto D, et al. Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: Systematic review and meta-analysis of 14 015 stroke cases and pooled analysis of primary biomarker data from up to 60 883 individuals. Int J Epidemiol. 2013;42(2):475-92. doi:10.1093/ije/dyt034.
39. Wei LK, Au A, Menon S, et al. Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and ischemic stroke: meta-analysis. J Stroke Cerebrovasc Dis. 2017;26(11):2482-93. doi:10.1016/j.jstrokecerebrovasdis.2017.05.048.
40. Paquette M, Bernard S, Paré G, et al. Triglycerides, hyperten-sion, and smoking predict cardiovascular disease in dysbeta-lipoproteinemia. J Clin Lipidol. 2020;14(1):46-52. doi:10.1016/j.jacl.2019.12.006.
41. Abou Saleh M, Mansoor E, Cooper GS. Case of familial hyper-lipoproteinemia type III hypertriglyceridemia induced acute pancreatitis: Role for outpatient apheresis maintenance therapy. World J Gastroenterol. 2017;23(40):7332-6. doi:10.3748/wjg.v23.i40.7332.
42. Fung M, Hill J, Cook D, et al. Case series of type III hyperlipo-proteinemia in children. BMJ Case Rep. 2011:bcr0220113895. doi:10.1136/bcr.02.2011.3895.
43. Paquette M, Bernard S, Blank D, et al. A simplified diagnosis algorithm for dysbetalipoproteinemia. J Clin Lipidol. 2020; 14(4):431-7. doi:10.1016/j.jacl.2020.06.004.
44. Sniderman A, Couture P, de Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol. 2010;6(6):335-46. doi:10.1038/nrendo.2010.50.
45. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New Eng J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792.
46. Nomura A, Tada H, Okada H, et al. Impact of genetic testing on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a randomised waiting list controlled open-label study protocol. BMJ Open. 2018;8(12):e023636. doi:10.1136/bmjopen-2018-023636.
Supplementary files
Review
For citations:
Blokhina A.V., Ershova A.I., Meshkov A.N., Drapkina O.M. Familial dysbetalipoproteinemia: highly atherogenic and underdiagnosed disorder. Cardiovascular Therapy and Prevention. 2021;20(6):2893. (In Russ.) https://doi.org/10.15829/1728-8800-2021-2893
Views:
1609
Email this article 
